Tominaga Y, Tsuzuki T, Uchida K, Haba T, Otsuka S, Ichimori T, Yamada K, Numano M, Tanaka Y, Takagi H
Department of Transplant Surgery and Pathology, Nagoya Second Red Cross Hospital, Japan.
Kidney Int. 1999 Apr;55(4):1375-83. doi: 10.1046/j.1523-1755.1999.00396.x.
In primary hyperparathyroidism, certain genetic abnormalities responsible for parathyroid tumorigenesis are proposed, and it has been reported that the overexpression of PRAD1/cyclin D1 induced by a DNA rearrangement of the parathyroid hormone (PTH) gene is one of the genetic disorders in a number of primary parathyroid adenomas. However, in secondary hyperparathyroidism caused by uremia, the mechanism of monoclonal proliferation in nodular parathyroid hyperplasia is not well understood. To elucidate the mechanism, we examined the expression of PRAD1/cyclin D1, retinoblastoma gene products, and Ki67 in primary adenoma and secondary hyperplasia.
In adenomas (N = 15) and associated glands (N = 7) with normal histology obtained from patients with primary hyperparathyroidism and in diffuse (N = 14), multinodular (N = 58), and single nodular (N = 28) glands from patients who underwent parathyroidectomy for renal hyperparathyroidism, the expression of these cell cycle regulators was evaluated by immunohistochemical technique. A labeling index was used to define the proportion of cells with positive nuclear staining by each antibody.
In 6 out of 15 (40%) primary adenomas, PRAD1/cyclin D1 was overexpressed (a labeling index of more than 500), possibly because of the PTH gene rearrangement, but not in secondary hyperplasia, including single nodular glands. Compared with diffuse hyperplasia, nodular hyperplasia showed a significantly higher expression of PRAD1/cyclin D1 (P < 0.05), retinoblastoma gene products (P < 0.05), and Ki67 (P < 0.05). However, no statistically significant correlation between the expression of PRAD1/cyclin D1 and that of Ki67 was observed in both primary adenoma and secondary hyperplasia.
These results suggest that in secondary hyperplasia caused by uremia, at least remarkable overexpression of PRAD1/cyclin D1 induced by PTH gene rearrangement may be not the major genetic abnormality responsible for tumorigenesis. Heterogenous genetic changes seem to contribute to monoclonal proliferation of parathyroid cells induced by the expression of PRAD1/cyclin D1 or by some other mechanism independent of the amplification of the proto-oncogene.
在原发性甲状旁腺功能亢进症中,已提出某些导致甲状旁腺肿瘤发生的基因异常,并且有报道称甲状旁腺激素(PTH)基因重排诱导的PRAD1/细胞周期蛋白D1过表达是许多原发性甲状旁腺腺瘤中的一种基因紊乱。然而,在尿毒症引起的继发性甲状旁腺功能亢进症中,结节性甲状旁腺增生的单克隆增殖机制尚不清楚。为了阐明该机制,我们检测了原发性腺瘤和继发性增生中PRAD1/细胞周期蛋白D1、视网膜母细胞瘤基因产物和Ki67的表达。
从原发性甲状旁腺功能亢进症患者获得的组织学正常的腺瘤(N = 15)及相关腺体(N = 7),以及因肾性甲状旁腺功能亢进症接受甲状旁腺切除术患者的弥漫性(N = 14)、多结节性(N = 58)和单结节性(N = 28)腺体,通过免疫组织化学技术评估这些细胞周期调节因子的表达。用标记指数来定义每种抗体核染色阳性的细胞比例。
15例原发性腺瘤中有6例(40%)PRAD1/细胞周期蛋白D1过表达(标记指数超过500),可能是由于PTH基因重排,但在继发性增生中未出现过表达,包括单结节性腺体。与弥漫性增生相比,结节性增生中PRAD1/细胞周期蛋白D1(P < 0.05)、视网膜母细胞瘤基因产物(P < 0.05)和Ki67(P < 0.05)的表达显著更高。然而,在原发性腺瘤和继发性增生中,均未观察到PRAD1/细胞周期蛋白D1表达与Ki67表达之间存在统计学上的显著相关性。
这些结果表明,在尿毒症引起的继发性增生中,至少由PTH基因重排诱导的PRAD1/细胞周期蛋白D1显著过表达可能不是导致肿瘤发生的主要基因异常。异质性基因变化似乎促成了由PRAD1/细胞周期蛋白D1表达或某种独立于原癌基因扩增的其他机制诱导的甲状旁腺细胞单克隆增殖。